TERN
USDTerns Pharmaceuticals Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$15.500
Kõrge
$18.740
Madal
$15.500
Maht
4.37M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
1.5B
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
1.85M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
Truist Securities Reiterates Buy on Terns Pharma, Raises Price Target to $28
Truist Securities analyst Srikripa Devarakonda reiterates Terns Pharma with a Buy and raises the price target from $20 to $28.
BMO Capital Maintains Outperform on Terns Pharma, Raises Price Target to $22
BMO Capital analyst Etzer Darout maintains Terns Pharma with a Outperform and raises the price target from $15 to $22.
Barclays Maintains Overweight on Terns Pharma, Raises Price Target to $27
Barclays analyst Etzer Darout maintains Terns Pharma with a Overweight and raises the price target from $14 to $27.
HC Wainwright & Co. Upgrades Terns Pharma to Buy, Announces $20 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado upgrades Terns Pharma from Neutral to Buy and announces $20 price target.
William Blair Upgrades Terns Pharma to Outperform
William Blair analyst Andy Hsieh upgrades Terns Pharma from Market Perform to Outperform.
Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades
Terns Pharmaceuticals shares rise after TERN-701 shows a 75% response rate in the CML trial, and William Blair upgrades the stock to Outperform.
Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting
Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population Encouraging safety and tolerability profile at all doses evaluated Company to host investor update call on
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.